The U.S. Food and Drug Administration recently held its first public comments session on CBD and CBD-infused products, though it appears the agency is not any closer to regulating what is formally known as cannabidiol, the non-psychoactive ingredient often associated with cannabis.

“As far as the markets and the proponents of the CBD, the same is being said over and over,” said Jean Gonnell, general counsel of STWC Holdings Inc. “Regulation and guidance is needed.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]